Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease, and may be the main reason for the failure of AD drug development. Fortunately, many ongoing preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Chenghuan, Shi, Jiyun, Zhang, Pingao, Zhang, Yongfang, Xu, Jianrong, Zhao, Lanxue, Zhang, Rui, Wang, Hao, Chen, Hongzhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932191/
https://www.ncbi.nlm.nih.gov/pubmed/35300725
http://dx.doi.org/10.1186/s40035-022-00292-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932191/
https://www.ncbi.nlm.nih.gov/pubmed/35300725
http://dx.doi.org/10.1186/s40035-022-00292-3

Ejemplares similares